Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages.
Sarah C RobinsonJeff M SlezakLaura PuzniakTimothy B FranklandBradley K AckersonLuis JodarJohn M McLaughlinPublished in: Open forum infectious diseases (2024)
We provide updated results (11 October 2023 through 29 February 2024) from our previously conducted test-negative case-control study in Kaiser Permanente Southern California to evaluate sublineage-specific effectiveness of the BNT162b2 XBB1.5-adapted vaccine. Results suggest that XBB1.5-adapted vaccines may have reduced effectiveness against JN.1 versus XBB sublineages.